THE ASSOCIATION OF CIRCULATING SCLEROSTIN LEVEL WITH MARKERS OF BONE METABOLISM IN PATIENTS WITH THYROID DYSFUNCTION

Olgica B. Mihaljević; Snežana Živančević-Simonović; Aleksandra Lučić-Tomić; Irena Živković; Rajna Minić; Ljiljana Mijatović-Todotović; Zorica Jovanović; Marija Anđelković; Marijana Stanojević-Pirković

doi:10.5937/jomb0-24943

Olgica B. Mihaljević University of Kragujevac, Faculty of Medical Science, Department of Pathophysiology
Snežana Živančević-Simonović University of Kragujevac, Faculty of Medical Science, Department of Pathophysiology
Aleksandra Lučić-Tomić University of Kragujevac, Faculty of Medical Science, Department of Internal Medicine
Irena Živković Institute of Virology, Vaccines and Sera Torlak, Department of Scientific Research
Rajna Minić Institute of Virology, Vaccines and Sera Torlak, Department of Scientific Research
Ljiljana Mijatović-Todotović University of Kragujevac, Faculty of Medical Sciences, Department of Nuclear Medicine
Zorica Jovanović University of Kragujevac, Faculty of Medical Science, Department of Pathophysiology
Marija Anđelković University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry
Marijana Stanojević-Pirković University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry

DOI: https://doi.org/10.5937/jomb0-24943

Abstract

Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps).
Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers.
Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p<0.001), but positively with FT4 (r=0.696, p < 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients.
Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps.
Keywords: beta-cross-laps, bone metabolism, osteocalcin, sclerostin, thyroid dysfunction

References

Seeman E, Delmas PD. Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354 (21): 2250–61.

Basset J, Williams G. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 2003; 14: 356–64.

Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Research 2014; 7: 12.

Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density. Int J Endocrinol 2013; Article ID 638727: 11 pages.

Gligorovic Barhanovic N, Antunovic T, Kalimanovska Spasojevic V. Age and assay related changes of laboratory thyroid function tests in the reference female population. J Med Biochem 2019; 38: 22–32.

Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O’Brien S, et al. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 2007; 22(6): 849–59.

Cardoso LF, Maciel LM, Paula FJ. The multiple effects of thyroid disorders on bone and mineral metabolism. Arq Bras monoclonal antibody 2014; 58(5): 452–463.

Sharifi M, Ereifej L, Lewiecki M. Sclerostin and skeletal health. Rev Endocr Metab Disord 2015; 16: 149–56.

Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004; 35(4): 828–35.

Skowrońska-Jóźwiak E, Krawczyk-Rusiecka K, Lewandowski KC, Adamczewski Z and Lewiński A. Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels. Thyroid Res 2012; 5: 14–6.

Rostami S, Fathollahpour A, Mohammad Abdi M, Naderi K. Alteration in prooxidant-antioxidant balance associated with selenium concentration in patients with congenital hypothyroidism. J Med Biochem 2018; 37: 355–63.

Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, et al. Circulating Sclerostin in Disorders of Parathyroid Gland Function. J Clin Endocrinol Metab 2011; 96(12): 3804–10.

van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 2012; 97: E1953–57.

O’Shea PJ, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS, et al. Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor b gene due to activation of Wnt/b-catenin protein signaling. J Biol Chem 2012; 287(21): 17812–22.

Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M.Hyperthyroidism and hypothyroidism in male mice and their effects on bone mass, bone turnover, and the Wnt inhibitors sclerostin and dickkopf-1. Endocrinology 2015; 156(10): 3517–27.

Sarıtekin , Açıkgöz S, Bayraktaro lu T, Kuzu F, Can M, Güven B, et al. Sclerostin and bone metabolism markers in hyperthyroidism before treatment and interrelations between them. Acta Biochim Pol 2017; 64(4): 597–602.

Engler H, Oettli RE, Riesen WF. Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study. Clin Chim Acta 1999; 289: 159–72.

Lee WJ, Oh KW, Rhee EJ, Jung CH, Kim SW, Yun EJ, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006; 37: 511–6.

Belaya ZE, Melnichenko GA, Rozinskaya LY, Fadeev VV, Alekseeva TM, Dorofeeva OK, et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. Hormones 2007; 6: 62–70.

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95(5): 2248–53.

Costa AG, Walker, Zhang CA, Cremers S, Dworakowski E, McMahon DJ, et al. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab 2013; 98(12): 4736–43.

Durosier C, Lierop AV, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 2013; 98(9): 3873–83.

Nikiforov YE. Thyroid tumors: classification, staging, and general considerations. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Diagnostic pathology and molecular genetics of the thyroid, 2nd edn. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2012. pp 108–19.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941–59.

Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M. Renal Elimination of Sclerostin Increases with Declining Kidney Function. J Clin Endocrinol Metab 2014; 99(1): 248–55.

Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1737–44.

García-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R, Muñoz-Torres M. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int 2014; 25: 645–51.

Rhee Y, Kim WJ, Han KJ, Lim SK, Kim SH. Effect of liver dysfunction on circulating sclerostin. J Bone Miner Metab 2014; 32: 542–9.

Grethen E, Hill KM, Jones RM, Cacucci BM, Gupta CE, Acton A, et al. Serum Leptin, Parathyroid Hormone, 1,25-Dihydroxyvitamin D, Fibroblast Growth Factor 23, Bone Alkaline Phosphatase, and Sclerostin Relationships in Obesity. J Clin Endocrinol Metab 2012; 97(5): 1655–62.

Lee MY, Park JH, Bae KS, Jee YG, Ko AN, Han YJ, et al. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res 2014; 86(2): 55–60.

Zaitseva OV, Shandrenko SG, Veliky MM. Biochemical markers of bone collagen type I metabolism. Ukr Biochem J 2015; 87: 21–32.

Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriquchi A, Nishizawa Y. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 2004; 22: 127–31.

Kojima N, Sakata S, Nakamura S, Nagai K, Takuno H, Ogawa T, et al. Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. J Endocrinol Invest 1992; 15: 491–6.

Barsal G, Taneli F, Atay A, Hekimsoy Z, Erciyas F. Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy. Tohoku J Exp Med2004; 203: 183–8.

Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F. Decreased Bone Density, Elevated Serum Osteoprotegerin, and b-Cross-Laps in Wilson Disease. J Bone Miner Res 2002; 17: 1961–7.

Naeem ST, Hussain R, Raheem A, Siddiqui I, Ghani F, Khan AH. Bone Turnover Markers for Osteoporosis Status Assessment at Baseline in Postmenopausal Pakistani Females. J Coll Physicians Surg Pak 2016; 26 (5): 408–12.